Table 1.
Characteristics of COVID-19 patients with and without cancer
| COVID-19 patients with cancer (n = 105) | COVID-19 patients without cancer (n = 536) | P | |
|---|---|---|---|
| Age (years; median/IQR) | 64.00/14.00 | 63.50/14.00 | 0.25 |
| Sex | |||
| Male | 57/54.72% | 245/45.71% | 0.11 |
| Female | 48/45.28% | 291/54.29% | 0.11 |
| In-hospital infection | 20/19.04% | 8/1.49% | <0.01 |
| Smoking | 36/34.28% | 46/8.58% | <0.01 |
| Comorbidities | |||
| Hypertension | 30/28.57% | 130/24.25% | 0.40 |
| Cardiovascular disease | 12/11.43% | 39/7.28% | 0.17 |
| Diabetes | 7/6.67% | 29/5.41% | 0.64 |
| Cerebrovascular disease | 5/4.76% | 21/3.92% | 0.60 |
| Chronic kidney disease | 6/5.71% | 22/4.10% | 0.44 |
| Chronic liver disease | 7/6.67% | 35/6.53% | 1.00 |
| Signs and symptoms | |||
| Fever | 68/64.76% | 401/74.81% | 0.04 |
| Dry cough | 57/52.29% | 313/58.40% | 0.45 |
| Sputum production | 16/15.24% | 58/10.82% | 0.24 |
| Fatigue | 30/28.57% | 179/33.40% | 0.36 |
| Myalgia | 6/5.71% | 38/7.09% | 0.83 |
| Nausea or vomiting | 6/5.71% | 41/7.65% | 0.68 |
| Chest distress | 15/14.29% | 36/6.16% | 0.02 |
| Headache | 7/6.67% | 28/5.22% | 0.49 |
| Sore throat | 11/10.48% | 43/8.02% | 0.44 |
| Treatments | |||
| Antibiotic treatments | 81/77.14% | 361/67.35% | 0.05 |
| Antiviral treatments | 75/71.43% | 372/69.40% | 0.68 |
| Systemic glucocorticoids | 19/18.10% | 78/14.55% | 0.35 |
| Oxygen therapy | 48/45.71% | 221/42.02% | 0.48 |
| Noninvasive mechanical ventilation | 11/10.48% | 47/8.77% | 0.58 |
| Invasive mechanical ventilation | 11/10.48% | 15/2.79% | <0.01 |
| Continuous renal replacement therapy | 4/3.81% | 3/0.56% | <0.01 |
| Extracorporeal membrane oxygenation | 3/2.86% | 2/0.37% | <0.01 |
| Time since cancer diagnosis to hospitalization | |||
| <3 months | 29/27.61% | NA | NA |
| 3–6 months | 17/16.19% | NA | NA |
| 6 months–1 year | 11/10.47% | NA | NA |
| 1–3 years | 19/18.09% | NA | NA |
| >3 years | 19/18.09% | NA | NA |
| Missing | 10/9.52% | NA | NA |
| Metastatic cancer | 17/16.19% | NA | NA |
| Cancer treatments within 40 days | |||
| Surgery | 8/7.62% | NA | NA |
| Radiotherapy | 13/12.38% | NA | NA |
| Chemotherapy | 17/16.19% | NA | NA |
| Targeted therapy | 4/3.81% | NA | NA |
| Immunotherapy | 6/5.71% | NA | NA |
Note: Data are presented as median (IRQ) or n (%). P values denoted the comparison between COVID-19 patients with cancer and without cancer.
Abbreviation: NA, not applicable.